The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Paul Declerck sits on this spectrum.
This scientist: 434 publications — 92nd percentile
92% of scientists in this discipline score the same or lower.
The last bar groups every scientist with 1,028 publications or more.
The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Paul Declerck sits on this spectrum.
This scientist: 69 D-Index — 63rd percentile
63% of scientists in this discipline score the same or lower.
The last bar groups every scientist with 167 D-Index or more.
Paul Declerck is affiliated with KU Leuven in Belgium. Their research spans multiple fields, with a primary focus on medicine and biochemistry, genetics, and molecular biology. Declerck's work particularly emphasizes several subfields including genetics, immunology, molecular biology, hematology, and radiology, nuclear medicine, and imaging.
The scientist's publications feature significant contributions to topics such as inflammatory bowel disease, blood coagulation and thrombosis mechanisms, monoclonal and polyclonal antibodies research, biosimilars and bioanalytical methods, immunodeficiency and autoimmune disorders, microscopic colitis, and protease and inhibitor mechanisms.
Recent papers authored or co-authored by Declerck include:
Their collaborative work involves frequent co-authors, including:
Paul Declerck has published multiple articles in specialized journals, illustrating their expertise and continuing research engagement. Notable publication venues include:
Their scientific inquiry mainly addresses critical medical challenges through a molecular and genetic lens. The research contributions encompass inflammatory bowel disease and mechanisms related to blood coagulation and thrombosis, with an emphasis on antibody research and bioanalytical approaches to biosimilars. Furthermore, ongoing investigation in protease and inhibitor mechanisms alongside autoimmune and immunodeficiency disorders forms an integral part of their work.
Paul Declerck;M C Alessi;M Verstreken;E K O Kruithof
P J Declerck;M De Mol;M C Alessi;S Baudner
M C Alessi;I Juhan-Vague;T Kooistra;Paul Declerck
Laetitia Devy;Silvia Blacher;Christine Grignet-Debrus;Khalid Bajou
Karolien Adriaens;Dinska Van Gucht;Paul Declerck;Frank Baeyens
I Juhanvague;Mc Alessi;P Joly;X Thirion
Chiho Isogai;Walter E. Laug;Hiroyuki Shimada;Paul J. Declerck
Mesut Eren;Corrie A. Painter;James B. Atkinson;Paul J. Declerck
Kristien Bonroy;Filip Frederix;Gunter Reekmans;Ellen Dewolf
A Stockmann;S Hess;Paul Declerck;R Timpl
Paul Declerck;M De Mol;D E Vaughan;Desire Collen
Khalid Bajou;Catherine Maillard;Maud Jost;Roger H Lijnen
HC Kwaan;J Wang;K Svoboda;Paul Declerck
Paul J. Declerck;Ann Gils
Ann Gils;Paul J Declerck
Xiubin Liang;Talerngsak Kanjanabuch;Su-Li Mao;Chuan-Ming Hao
K T Preissner;J Grulich-Henn;H J Ehrlich;Paul Declerck
Kathleen Aertgeerts;Hendrik L. De Bondt;Camiel J. De Ranter;Paul J. Declerck
Christine M Halleux;Paul J Declerck;Sinh L Tran;Roger Detry
Paul Declerck;Romano Danesi;Danielle Petersel;Ira Jacobs
If you think any of the details on this page are incorrect, let us know.
University of Manchester
Linköping University
University of Santiago de Compostela
University of Washington
Sun Yat-sen University
Radboud University
Mayo Clinic
University of South Florida
Pompeu Fabra University
University of Milano-Bicocca
Centers for Disease Control and Prevention
Max Planck Institute for Software Systems
University of Cambridge
Universitat Politècnica de Catalunya
University of Zaragoza
University of North Carolina at Chapel Hill
